hERG Screening Market Size to Surge USD 3.32 Billion by 2034

hERG Screening Market Key Takeaways

• In terms of revenue, the global hERG screening market was valued at USD 1.16 billion in 2024.
• It is projected to reach USD 3.32 billion by 2034.
• The market is expected to grow at a CAGR of 11.10% from 2025 to 2034.
• North America dominated the hERG screening market with the largest share of 39% in 2024.
• Asia Pacific is expected to grow at a significant CAGR from 2025 to 2034.
• By assay type, the functional assays segment led the market in 2024.
• By technology, the automated electrophysiology platforms captured the biggest market share of 36% in 2024.
• By technology, the high-throughput screening (HTS) segment will grow at the fastest CAGR between 2025 and 2034.
• By service type, the outsourced screening services segment captured the highest market share of 58% in 2024 and is expected to grow at the fastest rate over the forecast
• period.
• By service type, the in-house screening segment is expected to grow at a notable CAGR between 2025 and 2034.
• By end-user, the pharmaceutical & biotechnology companies segment held the highest market share of 61% in 2024.
• By end-user, the contract research organizations (CROs) segment will grow at a significant CAGR between 2025 and 2034.
• By application, the preclinical safety & toxicology segment contributed the largest market share of 47% in 2024.
• By application, the regulatory submission studies segment will expand at a significant CAGR between 2025 and 2034.
• By scale of operation, the preclinical-scale screening segment generated the major market share of 40% in 2024.
• By scale of operation, the high-throughput screening scale segment will expand at a significant CAGR between 2025 and 2034.

How AI Is Revolutionizing hERG Screening

Artificial Intelligence (AI) is transforming hERG (human Ether-à-go-go-Related Gene) screening by significantly enhancing the accuracy, speed, and predictive power of ion channel inhibition assessments. Through advanced algorithms and deep learning models, AI can analyze vast and complex biological datasets to detect subtle patterns that traditional methods may overlook. This capability enables more efficient and reliable prediction of cardiotoxicity risks during early-stage drug discovery.

The growing emphasis on in silico modeling—which involves computer-based simulations for biological processes—is accelerating the integration of AI into hERG screening workflows. AI-driven tools are now being used to complement or even replace conventional in vitro and in vivo approaches, resulting in faster turnaround times and reduced costs.

Furthermore, the FDA’s evolving guidelines around the use of AI in regulatory submissions are fostering greater industry confidence and adoption. As regulatory clarity improves, life science companies are increasingly investing in AI-powered platforms to meet safety standards and streamline drug development pipelines.

Many organizations are now adopting hybrid screening models that combine AI-based in silico predictions with traditional lab-based methods. This integrated approach enhances predictive accuracy while minimizing experimental burden, creating substantial opportunities for innovation in cardiac safety pharmacology and early toxicity screening.

Market Overview

The hERG screening market refers to the global industry focused on evaluating drug candidates for their potential to inhibit the human ether-à-go-go-related gene (hERG) potassium channel. This ion channel, encoded by the KCNH2 gene, plays a critical role in regulating cardiac repolarization, which is essential for maintaining normal heart rhythm. Inhibition of the hERG channel can result in QT interval prolongation and increase the risk of serious arrhythmias such as Torsades de Pointes (TdP).

Given these safety concerns, hERG screening has become a vital part of preclinical cardiac safety testing. Regulatory authorities including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) require hERG assessment during early drug development stages, particularly under the ICH S7B and E14 guidelines.

The market is experiencing steady growth due to the expansion of research and development infrastructure, increased government support, and rising investment in pharmaceutical innovation. Collaborative efforts among pharmaceutical and biotechnology companies, along with continuous technological advancements, are improving the efficiency, accuracy, and speed of hERG screening. These improvements are especially significant in addressing the growing global burden of heart disease, where early detection of cardiotoxicity is essential for developing safe and effective drugs.

Key Trends in the hERG Screening Market

• Increased prevalence of heart disease: The global rise in cardiovascular diseases and related conditions has led to a growing demand for safe and effective drug therapies. This surge is directly driving the need for hERG screening, as it plays a crucial role in assessing the cardiac safety of new drug candidates and preventing drug-induced arrhythmias.
• Rising awareness of cardiac safety: There is growing awareness among healthcare professionals, regulatory bodies, and pharmaceutical companies about the risks associated with drug-induced cardiac arrhythmias. This has led to broader adoption of hERG screening as an essential step in ensuring drug safety and minimizing potential adverse effects.
• Expansion of research and development activities: The increase in R&D efforts focused on novel drug discovery and formulation is supporting the wider implementation of hERG screening technologies. As more experimental therapies enter the pipeline, hERG evaluation is becoming a standard part of the development process to meet safety benchmarks.
• Stricter regulatory requirements: The demand for personalized medicine and growing regulatory scrutiny have made cardiac safety assessments more critical than ever. Compliance with guidelines from agencies such as the FDA and ICH now requires thorough hERG testing, further reinforcing its role in preclinical drug development.
• Rising demand for novel drug formulations: As the pharmaceutical industry intensifies efforts to develop new treatments for a variety of diseases, the need for reliable and early-stage cardiac safety testing has increased. hERG screening is an indispensable tool in this process, helping ensure that new formulations do not carry the risk of cardiotoxicity.

Drivers

Increased number of drug candidates entering clinical trials
The growing pipeline of drug candidates advancing into clinical trials is a primary factor driving the hERG screening market. With rising demand for early-stage cardiac safety assessments, the need to identify compounds with potential cardiotoxic effects has become critical. The increase in heart disease prevalence has led to a surge in clinical trials, further emphasizing the importance of evaluating drug-induced cardiac risks. As a result, research institutions and pharmaceutical companies are increasingly adopting hERG screening technologies to ensure safety and meet regulatory expectations.

Restraint

High cost of equipment and implementation
The adoption of hERG screening technologies is often hindered by the high costs associated with acquiring and maintaining advanced equipment such as automated patch-clamp systems. These systems are particularly expensive, making them less accessible to smaller pharmaceutical and biotech firms with limited budgets. Additionally, the use of precision recombinant hERG ion channel components further increases costs. The need for specialized expertise to operate these systems adds to the overall expense, limiting broader market adoption.

Opportunity

Technological advancements in screening methods
Ongoing advancements in screening technologies, such as high-throughput methods and automated patch-clamp techniques, are opening new opportunities for the hERG screening market. These innovations allow for faster and more accurate screening, helping to reduce false negatives and improve decision-making in drug development. The increasing use of automated systems enhances productivity and lowers long-term costs. Furthermore, companies are launching advanced products and services, including GLP-certified screening services and integrated automated suites, to meet the growing demand for efficient and reliable cardiac safety testing.

Recent Developments

• In May 2025, the Integrated Similarity Evaluation (ISE) map was developed by the research team at the National Institute of Health (NIH) for assessing the reliability of hERG prediction models, especially for detecting potential false negatives.
• In January 2025, hERGAT, a novel learning model to combine a graph attention mechanism and a gated recurrent unit, was developed by Lee and Yoo. The models provide the importance of various molecular structures by capturing complex interactions at the molecular and atomic levels, to offer features contributing to hERG inhibition.
• In January 2024, according to the new ICH S7B Guideline Q&As, the novel Best Practice hERG assay was introduced by Mediford to comply with GLP (Good Laboratory Practice) to provide Mediford as part of their drug development support services.
  

  hERG Screening Market Key Players

  
  • Charles River Laboratories 
  • Eurofins Scientific 
  • Cyprotex (Evotec SE)
  • Thermo Fisher Scientific
  • Metrion Biosciences
  • Aurora Biomed
  • QPatch (Sophion Bioscience)
  • Nanion Technologies
  • Axol Bioscience
  • B’SYS GmbH
  • Multispan Inc.
  • ChanTest (now part of Charles River)
  • Bioneer Corporation
  • Cellectricon
  • Corning Inc.
  • Physiologically Relevant
  • BioAxis Research
  • ChemPartner
  • Eurofins Discovery
  • NEXEL Co., Ltd.